Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Takumi Nemoto Picked as New Health Minister
October 2, 2018
- Council Approves Draft Revision of “Basic Policy on Blood Products”
October 2, 2018
- MHLW Proposes “Institutionalization” of Conditional Approval, Sakigake Schemes
October 1, 2018
- MHLW Sees October 2019 “Natural” Timing for Tax Hike-Linked Price Revision, but Likely to Moot Other Options Too
September 27, 2018
- MHLW Issues Guidelines on Detailing Activities by Sales Reps; to Take Effect Next April
September 27, 2018
- ASKA’s Generic Valsartan Might Cause Cancer in 1 in 15,000-30,000 Patients: MHLW
September 27, 2018
- Healthcare Spending a Record 42.2 Trillion Yen in FY2017, Drug Costs Up 2.9%: MHLW
September 26, 2018
- Pfizer’s Lorlatinib Gets 1st Conditional OK; MHLW Approves Astellas AML Drug and More
September 25, 2018
- MHLW Panel Members Share Views on One Key Topic toward PMD Law Amendment; Next Meeting Scheduled Soon: Official
September 25, 2018
- Recordati Succeeds Carbaglu Orphan Drug Designation from Pola Pharma
September 20, 2018
- MHLW Orders Package Insert Revision for Xofigo, Warning of Increased Risk of Death, Bone Fracture with 3-Drug Combination
September 20, 2018
- Pfizer to Use MID-NET Database for Ibrance PMS
September 19, 2018
- Second Applicant from Pharma Companies to Use MID-NET: PMDA
September 19, 2018
- Alexion’s PNH Therapy Ravulizumab, Two other APIs Bag Orphan Drug Designations
September 19, 2018
- MHLW Drug Pricing Official Calls on Industry to Present Specific Proposal on PMP
September 19, 2018
- MHLW to Launch Mock Review Project to Up Standards of “Certified IRBs” under Clinical Research Law: Official
September 14, 2018
- Tailwind for Prevenar 13? Vaccine Panel Members Up for Its Use in High-Risk Elderly
September 11, 2018
- JPMA Official Hails MHLW Discussions on Use of “Specified Clinical Research” Data in Application Dossiers
September 10, 2018
- 4th Sakigake Invitation to Start on October 1: MHLW
September 10, 2018
- MHLW to Promote Optimization of Plasma Fraction Product Transactions: New Blood Product Chief
September 7, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…